ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance
Open accessThe DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index.
Abstract
Hypertriglyceridemia results from accumulation of triglyceride (TG)-rich lipoproteins (TRLs) in the circulation and is associated with increased CVD risk. ApoC-III is an apolipoprotein on TRLs and a prominent negative regulator of TG catabolism. We recently established that in vivo apoC-III predominantly inhibits LDL receptor-mediated and LDL receptor-related protein 1-mediated hepatic TRL clearance and that apoC-III-enriched TRLs are preferentially cleared by syndecan-1 (SDC1). In this study, we determined the impact of apoE, a common ligand for all three receptors, on apoC-III metabolism using apoC-III antisense oligonucleotide (ASO) treatment in mice lacking apoE and functional SDC1 ( Apoe −/− Ndst1 f/f Alb-Cre + ). ApoC-III ASO treatment significantly reduced plasma TG levels in Apoe −/− Ndst1 f/f Alb-Cre + mice without reducing hepatic VLDL production or improving hepatic TRL clearance. Further analysis revealed that apoC-III ASO treatment lowered plasma TGs in Apoe −/− Ndst1 f/f Alb-Cre + mice, which was associated with increased LPL activity in white adipose tissue in the fed state. Finally, clinical data confirmed that ASO-mediated lowering of APOC-III via volanesorsen can reduce plasma TG levels independent of the APOE isoform genotype. Our data indicate that apoE determines the metabolic impact of apoC-III as we establish that apoE is essential to mediate inhibition of TRL clearance by apoC-III and that, in the absence of functional apoE, apoC-III inhibits tissue LPL activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3. ApoC-III ASO treatment does not affect hepatic VLDL production and TRL clearance in Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were on apoC-III ASO or control (Ctrl) ASO for 4 weeks. Fasted mice (5 h) were given a 250 μl bolus of corn oil by oral gavage to measure fat tolerance. Postprandial TG levels were measured 0, 1, 2, and 3 h after gavage (n = 3 per group). B: Hepatic VLDL production was determined after intravenous injection of Tyloxapol (0.5 mg/g bodyweight) to block lipase activity. TRL uptake and plasma TG levels were measured at the indicated time points (n = 3–5 per group). C: Intestinal lipid absorption was analyzed by intravenous injection of Tyloxapol followed by oral gavage of corn oil (250 μl). Plasma TG levels were measured at the indicated time points (n = 3). D: Hepatic TRL clearance was analyzed by retinyl ester excursion. [3H]retinol (5 μCi) in 250 μl corn oil was orally gavaged and the remaining counts in the plasma were determined by liquid scintillation counting after 2, 4, 6, and 8 h (n = 3). E: Schematic overview of [3H]TRL clearance experiments in vivo. F: Isolated [3H]TRLs enriched (control ASO) or depleted (apoC-III ASO) in apoC-III were injected intravenously into Apoe−/−Ndst1f/fAlb-Cre+ mice on apoC-III ASO (n = 2). Clearance of [3H]TRLs was assessed by measuring the counts remaining in the plasma relative to the counts recovered 1 min after injection (values represent mean ± SEM; *P < 0.05, **P < 0.01).](https://figures.cochat.ai/paper-figures/b62465be48d4442b85400dd94637ff71/apoc-iii-aso-promotes-tissue-lpl-activity-in-the-absence-of-apoe-mediated-trl-figure-3.jpg)
![Fig. 4. ApoC-III inhibition of TRL clearance requires apoE. A–D: Primary hepatocytes were isolated from Apoe−/−Ndst1f/fAlb-Cre+ mice and binding (4°C) and uptake (37°C) of [3H]retinol-labeled apoC-III-enriched and apoC-III-deficient TRL particles were analyzed. A: Binding of [3H]TRLs (100 μg/ml) enriched or deficient in apoC-III was determined after incubation in primary hepatocytes in the absence or presence of apoE at 4°C for 1 h. Binding and uptake was assessed after incubation of [3H]retinol-labeled TRLs at 37°C for 4 h in a dose-dependent manner (10/20/50/100 μg/ml) in the absence (B) and presence (C) of apoE. D: Reconstituted [3H]TRLs (50 μg) were evaluated in their binding and uptake capacity in primary hepatocytes (n = 3 per condition in all experiments, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).](https://figures.cochat.ai/paper-figures/859203abd70f4aebaf61c58617c5f3d8/apoc-iii-aso-promotes-tissue-lpl-activity-in-the-absence-of-apoe-mediated-trl-figure-4.jpg)
![Fig. 5. ApoC-III lowering increased FA uptake in liver and WAT in Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Apoe−/−Ndst1f/fAlb-Cre+ mice were fasted for 5 h. After a 5 min intravenous injection of [3H]triolein-labeled liposyn particles (100 μl), blood and the indicated tissues were harvested (A) and (B) tissue weights were determined (B). [3H]triolein tissue uptake was determined of the homogenized tissues by liquid scintillation counting (n = 4–6). C: [3H]palmitic acid uptake into various tissues of control (Ctrl) ASO- and apoC-III ASO-treated mice was analyzed by retro-orbital injection of 1 μCi (n = 4–6). D: Primary hepatocytes were isolated from mice administered with control ASO or apoC-III ASO and binding and uptake of [14C]oleic acid was assessed in vitro. Hepatocytes were incubated with 0.5 μCi of radiolabeled FAs at 37°C, and incorporation was measured at the indicated time points (n = 3 per condition; values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).](https://figures.cochat.ai/paper-figures/c1934e49e30648f198cede15faaacf0b/apoc-iii-aso-promotes-tissue-lpl-activity-in-the-absence-of-apoe-mediated-trl-figure-5.jpg)
![Fig. 6. Transcriptomics and metabolomics of hepatocytes from apoC-III ASO-treated Apoe−/−Ndst1f/fAlb-Cre+ mice. A: Volcano-plot depicting a differential gene expression derived from RNA-seq analysis of livers isolated from fasted Apoe−/−Ndst1f/fAlb-Cre+ mice receiving apoC-III ASO or control (Ctrl) ASO for 8 weeks. Genes that were significantly (adjusted P < 0.05) up- or downregulated upon apoC-III ASO are highlighted (excluding Apoc3). B: A heat map showing differentially expressed protein-coding genes with adjusted P-value <0.05 upon apoC-III ASO (left panel, n = 5) compared with control ASO (right panel, n = 4). Heat maps of genes involved in de novo lipogenesis (C) and FA transport (D). E: ApoC-III ASO or control ASO were administered to Apoe−/−Ndst1f/fAlb-Cre+ mice and primary hepatocytes were isolated and incubated with 20 μM U-[13C16]palmitic acid tracer for 1 h and 4 h at 37°C for cellular FA metabolism analysis. After lipid extraction and GC/MS, enrichment of FA from U-[13C16]palmitic acid tracer and total FA composition were determined. F: Total percentage of C16:0 is shown. G: Enrichment of U-[13C16]palmitic acid tracer in metabolites of the TCA cycle (n = 3–4 per condition, values represent mean ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001).](https://figures.cochat.ai/paper-figures/31eb247d13f241659476aed90ccc16fb/apoc-iii-aso-promotes-tissue-lpl-activity-in-the-absence-of-apoe-mediated-trl-figure-6.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Which factors determine the fate of a remnant particle (in the VLDL or IDL density range) remains incompletely defined, although apoCIII inhibits whereas apoE and possibly HL facilitate hepatic remnant uptake.74,75”
From Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society (2021) · cites this paper as [75]
Experimental — accuracy not yet measuredIn the citing paper
“In mice, apoCIII impacts plasma TG levels and remnant accumulation when LpL activity is reduced, but not when normal.75”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 1×
“DESeq2 (34) was used to calculate differential gene expression based on uniquely aligned reads, and P-values were adjusted for multiple hypothesis testing with the BenjaminiHochberg method.”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709 · cited 1×
“The spliced read aligner STAR (32) was used to align sequencing reads to the mouse GRCm38 genome.”
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · cited 1×
“Polar metabolites and FAs were extracted using methanol/ water/chloroform and analyzed as previously described (35).”
Self-citationChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071 · cited 1×
“The importance of apoC-III in humans was established by the findings that inactivating mutations were shown to correlate with lower plasma TGs (15) and to protect against CVD (16–18).”
Identification of multiple subclasses of plasma low density lipoproteins in normal humans.
Krauss, R. M., & Burke, D. J. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38178-5 · Cited by 992
Self-citationLoss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders
Mahley, R. W. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1427-y · Cited by 837 · cited 6×
“synthesized and secreted primarily by liver, brain, skin, and macrophages (11).”
InfluentialPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 4×
“More importantly, it needs to be determined whether the distinctly different TG clearance pathways modulated by APOC-III have a differential impact on CVD and longevity, which are associated with altered plasma apoC-III levels in the human population.”
Influential
Cited by
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“In a mouse model, the effect of reducing apoCIII on hepatic remnant removal was significant only when LpL activity was markedly reduced, 75 possibly explaining the lack of apoB reduction with an apoCIII ASO in moderate hypertriglyceridaemia.”
BackgroundMetabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
“Next to the well-established inhibition of LPL and thus attenuation of peripheral TRL disposal conferred by APOC3 [4,132,133], stimulation of VLDL secretion and inhibition of remnant endocytosis have been reported as APOC3 effects in the liver [132,134,135].”
BackgroundThe Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans
Borén, J., Packard, C. J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00474 · Cited by 196
“It appears that apoC-III can inhibit hepatic clearance of remnants by LPL-independent pathways (Figure 1) (69), possibly by interfering with the binding of apoB and apoE to hepatic lipoprotein receptors including HSPG, LDLR and LRPl (31, 70).”
BackgroundMethodInfluentialAddressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
“However, APOC3 deficiency or inhibition lowers TG levels in the absence of APOE likely as result of increased LPL activity and uptake of fatty acids in adipose tissue (92).”
BackgroundRegulation of lipoprotein lipase-mediated lipolysis of triglycerides
Basu, D., & Goldberg, I. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000676 · Cited by 114
“[18] determined the role of ApoE in ApoC3’s action on hepatic clearance of TRL via syndecan 1 (SDC1).”
BackgroundIncreased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes
Kanter, J. E., Shao, B., Kramer, F., Barnhart, S., Shimizu-Albergine, M., Vaisar, T., Graham, M. J., Crooke, R. M., Manuel, C. R., Haeusler, R. A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127308 · Cited by 105
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Landmesser, U., Poller, W., Tsimikas, S., Most, P., Paneni, F., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa229 · Cited by 99
Self-citationA new dawn for managing dyslipidemias: The era of rna-based therapies
Macchi, C., Sirtori, C. R., Corsini, A., Santos, R. D., Watts, G. F., & Ruscica, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104413 · Cited by 94
“clearance or changes in LPL activity, need to be exactly determined (122).”
BackgroundBeyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation
Reyes‐Soffer, G., & Westerterp, M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105689 · Cited by 100
Modification of lipoprotein metabolism and function driving atherogenesis in diabetes
Luciani, L., Pedrelli, M., & Parini, P. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117545 · Cited by 72
Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
Gugliucci, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134399 · Cited by 74
Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance
Packard, C. J., Pirillo, A., Tsimikas, S., Ference, B. A., & Catapano, A. L. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvad177 · Cited by 61
Self-citationNew Therapies for Primary Hyperlipidemia
Aguilar-Salinas, C. A., Gómez-Díaz, R. A., & Corral, P. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab876 · Cited by 57
ApoCIII: A multifaceted protein in cardiometabolic disease
D'Erasmo, L., Di Costanzo, A., Gallo, A., Bruckert, E., & Arca, M. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154395 · Cited by 50
Basu, D., & Bornfeldt, K. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00504 · Cited by 52
“APOC3 ASO significantly reduced fasting TG levels and postprandial TGs, as compared with monkeys receiving control ASO.”
BackgroundInfluentialIntestinal lymphatic vessels and their role in chylomicron absorption and lipid homeostasis
Hokkanen, K., Tirronen, A., & Ylä‐Herttuala, S. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000626 · Cited by 46
Apolipoprotein C3: form begets function
Bornfeldt, K. E. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100475 · Cited by 45
“Research on mouse models has also shown that APOC3 can prevent tissue LPL action in vivo, at least when APOE, a ligand for LDLR and LRP1, is absent (45, 53).”
BackgroundAl-Mrabeh, A. H. (2021) · Biomedicines · doi:10.3390/biomedicines9020226 · Cited by 46
Role of the Gut in Diabetic Dyslipidemia
Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 37
“However, apoC3 inhibition by ASO decreased fasting and postprandial plasma TG without altered intestinal fat absorption in mice (143).”
BackgroundAdvances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors
Tomlinson, B., Wu, Q., Zhong, Y.-M., & Li, Y. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.2 · Cited by 46
“66 The scavenger receptor B1 may also be involved in the liver uptake of TRL remnants which may be inhibited by apoC3.”
BackgroundKegulian, N. C., Ramms, B., Horton, S. B., Trenchevska, O., Nedelkov, D., Graham, M. J., Lee, R. G., Esko, J. D., Yassine, H. N., & Gordts, P. L. S. M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312723 · Cited by 38
Self-citationDietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII
Hieronimus, B., & Stanhope, K. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000653 · Cited by 34
Srivastava, R. A. K. (2023) · Cells · doi:10.3390/cells12121648 · Cited by 48
Alradwan, I. A., Fayez, N. A., Alomary, M. N., Alshehri, A. A., Aodah, A. H., Almughem, F. A., Alsulami, K. A., Aldossary, A. M., Alawad, A. O., Tawfik, Y. M. K., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081037 · Cited by 50
“RNA-targeted ASOs have demonstrated significant potential in pivotal cardiovascular trials, particularly those targeting Apolipoprotein C-III (ApoC-III) [110].”
BackgroundSpagnuolo, C. M., & Hegele, R. A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2206015 · Cited by 28
“The TRL metabolism produces TRL remnants less than 70 nm in diameter, such as chylomicron remnants, very low-density lipoprotein (VLDL) remnants and intermediate-density lipoprotein (IDL).”
BackgroundInfluentialSarkar, S., Elliott, E. C., Henry, H. R., Ludovico, I. D., Melchior, J., Frazer‐Abel, A. A., Webb‐Robertson, B., Davidson, W. S., Holers, V. M., Rewers, M., et al. (2023) · Clinical Proteomics · doi:10.1186/s12014-023-09429-6 · Cited by 33
“Several studies report changes in the APOCs and APOE [7, 11, 18] which are also thought to modulate triacylglycerol lipolysis in VLDLs [66, 67].”
BackgroundApolipoprotein E content of VLDL limits LPL-mediated triglyceride hydrolysis
Whitacre, B. E., Howles, P. N., Street, S. E., Morris, J. C., Swertfeger, D. K., & Davidson, W. S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100157 · Cited by 29
“The effects of APOC3 on LPL activity appear complex and may involve additional factors such as other APOCs and APOE (37).”
BackgroundAtherosclerosis: cell biology and lipoproteins
Getz, G. S., & Reardon, C. A. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000704 · Cited by 27
Shimizu‐Albergine, M., Basu, D., Kanter, J. E., Kramer, F., Kothari, V., Barnhart, S., Thornock, C., Mullick, A. E., Clouet-Foraison, N., Vaisar, T., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci153285 · Cited by 31
“First, it inhibits LPL activity—perhaps by preventing the LPL that is tethered to the microvascular endothelium from accessing the TGs in these particles—thereby reducing TG hydrolysis and conversion of chylomicrons to chylomicron remnants and VLDL to IDL and further to LDL (24, 25).”
BackgroundRamms, B., Patel, S., Sun, X., Pessentheiner, A. R., Ducasa, G. M., Mullick, A. E., Lee, R. G., Crooke, R. M., Tsimikas, S., Witztum, J. L., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158414 · Cited by 24
“First, apoC-III ASO lowered plasma triglyceride levels in Apoe–/– Ndst1fl/fl Alb-Cre+ mice by promoting tissue LPL activity, independent of its effects on hepatic TRL clearance (Figure 1A) (17).”
BackgroundMethodSelf-citationRole of apolipoproteins in the pathogenesis of obesity
Huang, M., Zheng, J., Chen, L., You, S., & Huang, H. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117359 · Cited by 23
Research Progress on the Mechanism of Acute Hypertriglyceridemic Pancreatitis
Meng, Y., Han, P., Ma, X., He, Y., Chen, H., & Ren, H. (2024) · Pancreas · doi:10.1097/mpa.0000000000002364 · Cited by 23
Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity
Ramms, B., Pollow, D. P., Zhu, H., Nora, C., Harrington, A. R., Omar, I., Gordts, P. L. S. M., Wortham, M., & Sander, M. (2022) · Diabetes · doi:10.2337/db21-1131 · Cited by 23
Self-citationPoller, W. C., Sahoo, S., Hajjar, R. J., Landmesser, U., & Krichevsky, A. M. (2023) · Cells · doi:10.3390/cells12222660 · Cited by 22
Melhem, S., Steven, S., Taylor, R., & Al-Mrabeh, A. H. (2021) · Nutrients · doi:10.3390/nu13051465 · Cited by 20
“However, it was reported recently that ApoC-III promotes lipoprotein lipase (LPL) activity independent of ApoEmediated clearance of lipoproteins [34].”
BackgroundLowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements
Valladolid‐Acebes, I., Åvall, K., Recio-López, P., Moruzzi, N., Bryzgalova, G., Björnholm, M., Krook, A., Fauste, E., Ericsson, M., Landfors, F., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc2931 · Cited by 19
Pessentheiner, A. R., Spann, N. J., Autran, C. A., Oh, T. G., Grunddal, K. V., Coker, J. K. C., Painter, C. D., Ramms, B., Chiang, A. W. T., Wang, C.-Y., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.181329 · Cited by 22
Self-citationPhysiology and Pathophysiology of Heparan Sulfate in Animal Models: Its Biosynthesis and Degradation
Mashima, R., Okuyama, T., & Ohira, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041963 · Cited by 19
“Alb-Cre;Ndst1(f/f); Apoe(−/−) ↑Plasma triglyceride levels [82]”
HDL-associated apoCIII plays an independent role in predicting postprandial hypertriglyceridemia
Zhang, T., Tang, X., Mao, L., Chen, J., Kuang, J., Guo, X., Xu, D., Peng, D., & Yu, B. (2020) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2020.02.004 · Cited by 19
VLDL receptor gene therapy for reducing atherogenic lipoproteins
Krauss, R. M., Lu, J. T., Higgins, J. J., Clary, C. M., & Tabibiazar, R. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101685 · Cited by 18
“[59] Ramms B, Patel S, Nora C, Pessentheiner AR, Chang MW, Green CR, et al.”
BackgroundSelf-citationShaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 16
The Future of Lipid-Lowering Therapy
Zwol, W. H.-V., Rimbert, A., & Kuivenhoven, J. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071085 · Cited by 14
Targeting Regulation of Macrophage to Treat Metabolic Disease: Role of Phytochemicals
Ye, Z., Li, Y., Yang, X., Li, C., Yu, R., Zheng, G., & Su, Z. (2025) · Cell Proliferation · doi:10.1111/cpr.70012 · Cited by 10
“Some of the chylomicrons are recognised by adipose tissues, where the chylomicrons are hydrolysed into fatty acids and chylomicron remnants by lipoprotein lipase (LPL) [67].”
Discovery of long-acting APOC3 siRNA for treating patients with hypertriglyceridemia
Prakash, T. P., Mullick, A. E., Riney, S., Yu, J., Nikan, M., Quirk, C., Crutchfield, A., Damle, S. S., Klein, S., & Swayze, E. E. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1063 · Cited by 8
“Mechanistic studies have demonstrated that elevated plasma apoC3 impacts plasma triglyceride metabolism by two distinct mechanisms: inhibition of lipoprotein lipase (LPL) and reduced hepatocyte uptake of triglyceride-rich lipoproteins (TRL) [ 29 , 30 ].”
Uncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2020) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2020.09.003 · Cited by 9
Innate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets
Poller, W. C., Heidecker, B., Ammirati, E., Kuss, A. W., Tzvetkova, A., Poller, W. C., Skurk, C., & Haghikia, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010335 · Cited by 8
Emerging agents targeting triglycerides
Prakash, Y. S., Bhatt, D. L., & Malick, W. A. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000979 · Cited by 7
Genetically Engineered Hamster Models of Dyslipidemia and Atherosclerosis
Xian, X., Wang, Y., & Liu, G. E. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-1924-7_26 · Cited by 7
Ginsberg, H. N., & Bornfeldt, K. (2026) · Circulation Research · doi:10.1161/circresaha.125.327267 · Cited by 4
“65 APOC3 silencing also suppressed atherosclerosis, 59 demonstrating that APOC3 plays a causal role in the accelerated atherosclerosis in this model of T2D.”
Pessentheiner, A. R., Spann, N. J., Autran, C. A., Ramms, B., Chiang, A. W. T., Grunddal, K. V., Wang, Y., Quach, A., Booshehri, L. M., Hammond, A., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.089 · Cited by 4
Self-citationUncovering the role of apolipoprotein C-III in insulin resistance
Aguilar-Recarte, D., Palomer, X., & Vázquez‐Carrera, M. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.04.002 · Cited by 9
Xiang, Q., Tian, F., Xu, J. R., Du, X., Zhang, S., Guo, L., Zhu, L., Xie, Y., Zang, X., Gui, Y., et al. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159236 · Cited by 4
Kršek, A., Batičić, L., & Tokmadžić, V. S. (2024) · Cardiogenetics · doi:10.3390/cardiogenetics14030012 · Cited by 5
“Predictive accuracy is further improved by including the AF-PRS in models together with clinical variables such as anthropometrics, blood pressure, smoking status, blood pressure medication, diabetes, and history of myocardial infarction and heart failure [37–41].”
Alterman, J. F., Gross, K. Y., & Khvorova, A. (2026) · Nucleic Acid Therapeutics · doi:10.1177/21593337261435980 · Cited by 3
“3,4 In addition to LPL mutations, pathogenic variants can also occur in related genes, such as APOA5, APOC2, LMF1 , or GPIHBP1 , which are required for normal LPL activity and can produce a similar clinical phenotype.”
Production and Metabolism of Triglyceride-Rich Lipoproteins: Impact of Diabetes
Pirillo, A., Norata, G. D., & Catapano, A. L. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_7 · Cited by 3
Vitali, C., Stankov, S. G., Khetarpal, S. A., Millar, J. S., Mayne, L. C., Englander, S. W., Hand, N. J., Lund‐Katz, S., Phillips, M. C., & Rader, D. J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.02.183178 · Cited by 1
Rodríguez, M. M., Rehues, P., Iranzo, V., Mora, J. D., Balsells, C., Guardiola, M., & Ribalta, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.15.298802 · Cited by 1
“Interference with the clearance of TG-rich lipoproteins was also proposed (10), and recent data actually suggests this role as the main mechanism of action (11) because there is no in vivo evidence of LPL inhibition by Apo CIII under physiological conditions (12, 13).”
BackgroundStudy on VLDLR Gene Therapy for Reducing Atherogenic Lipoprotein
关, 桢. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133488
Sarkar, S., Elliott, E. C., Henry, H. R., Ludovico, I. D., Melchior, J., Frazer‐Abel, A. A., Webb-Robertson, B.-J., Davidson, W. S., Holers, V. M., Rewers, M. J., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26618692
Metadata
- Authors
- Ramms, B., Patel, S., Nora, C., Pessentheiner, A. R., Chang, M. W., Green, C. R., Golden, G. J., Secrest, P., Krauss, R. M., Metallo, C. M., Benner, C., Alexander, V. J., Witztum, J. L., Tsimikas, S., Esko, J. D., & Gordts, P. L. S. M.
- Affiliations
- Bielefeld University (DE)
- University of California San Diego (US)
- Ionis Pharmaceuticals (United States) (US)
- Corresponding author
- Ramms, Bastian
- Gordts, Philip L.S.M.
- ORCID
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2019-08
- Volume
- 60
- Issue
- 8
- Pages
- 1379-1395
- ISSN
- 0022-2275 (ISSN-L)
- PMC
- PMC6672034
- OpenAlex
- W2945419995
- Cited by
- 59
- References
- 64
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 12 · 2022: 6 · 2021: 12 · 2020: 11 · 2019: 6
- FWCI
- 6.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 384 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- American Heart Association (17PRE33410619, 15BGIA25550111)
- National Institute of General Medical Sciences (GM33063)
- National Heart, Lung, and Blood Institute (P01 HL107150)
- Ionis Pharmaceuticals, Inc.
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- apolipoprotein C-III, antisense oligonucleotides, lipoprotein lipase, triglyceride-rich lipoproteins, apolipoprotein E, syndecan-1, hypertriglyceridemia, volanesorsen, white adipose tissue, triglyceride catabolism, ApoE-deficient mice
- MeSH terms
- Mice, Knockout, ApoE, Animals, Apolipoproteins E, Lipoprotein Lipase, Receptors, LDL, Triglycerides, Mice, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.